Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

Published: 06 June 2018

Recent Videos

video

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us about the long-term outcomes when treating chronic lymphocytic leukemia (CLL) ...

video

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

Dr. Zhuang, VP, Oncology Clinical Research, Janssen, tells us about the results of the LCAR-838M study in relapsed/refractory multiple myeloma ...

video

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

Dr. Zhuang, VP, Oncology Clinical Research, Janssen, offers opinion on how LCAR-838M may impact the treatment of multiple myeloma (MM)

video

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

Dr. Zhuang, VP, Oncology Clinical Research, Janssen, shares how the CAR-T product (LCAR-B38M) is being studied and how it differs ...

video

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us how venetoclax should be used in the treatment of relapsed/refractory ...

video

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

Dr. Weisel, Head of the Myeloma Center, University of Tubingen, discusses anti-BCMA CAR-T cell therapy treatment for multiple myeloma (MM) ...

video

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, tells us about the outcomes of the GRIFFIN study, ...

video

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

Dr. Weisel, Head of the Myeloma Center, University of Tubingen, explains how maintenance regimens in multiple myeloma may change as ...

video

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, shares thoughts on whether anti-BCMA CAR-T cell therapy looks ...

video

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses emerging therapies for newly diagnosed ...

Related Videos

video-image

Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma

video-image

Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma

video-image

Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma

video-image

Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM

video-image

Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M

video-image

Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM

video-image

Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM

video-image

Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018

video-image

Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab

video-image

Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study

video-image

Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients

video-image

Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy

video-image

Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM

video-image

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

video-image

Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018

video-image

Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018

video-image

Keith Pratz, MD, on genetic testing in AML prior to the start of therapy

video-image

Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma

video-image

Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients

video-image

Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018